secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2022-09-15T23:59:59+00:00
Accession:  0001493152-22-025929
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio cuts workforce by 20% and identifies over $1.5M in annual cost savings to focus on LB1148
--------------------------------------------------------------------------------

- Reduction in force of 20% with estimated cash severance of $380,148.
- Anticipates annual cost savings of ~$773,000 from workforce reduction plus up to $800,000 from other cuts, totaling >$1.5M.
- Company to focus all resources on advancing lead asset LB1148, with Phase 3 enrollment targeted within 18-24 months.
- Payment of severance expected to be substantially completed by end of Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/0001493152-22-025929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-025929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer